Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Colorectal Cancer

MABp1 for Patients w/ Colorectal Cancer Who Are Losing Weight
A Pivotal Phase III Study to Evaluate Overall Survival Using MABp1 as a Monotherapy in Metastatic Colorectal Cancer Patients With Cachexia
Status Conditions Phase Study ID
Closed Metastatic Colorectal Cancer Phase III NCT01767857
Summary

The purpose of this study is to determine if the True Human Monoclonal antibody MABp1 can prolong the life of colorectal carcinoma patients who are losing weight.


Investigator
Andrew L. Coveler, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  1. Subjects with pathologically confirmed colorectal carcinoma that is metastatic or unresectable and which is refractory to standard therapy. To be considered refractory, a subject must have failed both an oxaliplatin and an irinotecan based regimen.
  2. Weight loss of ≥5% over the last 6 months.
  3. Eastern Cooperative Oncology Group (ECOG) performance status 0,1, or 2.
  4. Palliative radiation and/or chemotherapy are permitted after the initial 2 week washout period.
Exclusions (conditions that would prevent participation in this study)
  1. Mechanical obstruction that would prevent adequate oral nutritional intake.
  2. Serious uncontrolled medical disorder, or active infection, that would impair the ability of the patient to receive protocol therapy.
Last Updated
September 10, 2014
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.